![](\"https:\/\/www.newsbeep.com\/ie\/wp-content\/uploads\/2026\/02\/KY-with-Dog-1800x800-1.jpg\"\/)
\n<\/p>\nHow the On\u00adco\u00adtype DX\u00ae test\u2019s pre\u00addic\u00adtive util\u00adi\u00adty pro\u00adpelled pre\u00adci\u00adsion on\u00adcol\u00ado\u00adgy\u00a0<\/p>\n
In 2003, Kather\u00adine Y., a 53-year-old po\u00addi\u00ada\u00adtrist, found a lump in her breast dur\u00ading a self-ex\u00adam. The fog of a can\u00adcer di\u00adag\u00adno\u00adsis fol\u00adlowed: back-to-back ap\u00adpoint\u00adments, scans and pathol\u00ado\u00adgy re\u00adports, a new, can\u00adcer-cen\u00adtric vo\u00adcab\u00adu\u00adlary to learn. Kather\u00adine un\u00adder\u00adwent a dou\u00adble mas\u00adtec\u00adto\u00admy to re\u00admove the can\u00adcer, then faced her hard\u00adest de\u00adci\u00adsion yet: Should she have chemother\u00ada\u00adpy to re\u00adduce the chance of can\u00adcer re\u00adturn\u00ading some\u00adwhere else in her body?<\/p>\n
Stan\u00addard tu\u00admor as\u00adsess\u00adments sug\u00adgest\u00aded chemother\u00ada\u00adpy would be nec\u00ades\u00adsary, and Kather\u00adine heard the fa\u00admil\u00adiar log\u00adic: treat broad\u00adly, treat ag\u00adgres\u00adsive\u00adly, re\u00adduce risk. But she al\u00adso un\u00adder\u00adstood how chemother\u00ada\u00adpy could neg\u00ada\u00adtive\u00adly im\u00adpact her qual\u00adi\u00adty of life. What she need\u00aded was clar\u00adi\u00adty.<\/p>\n
In Jan\u00adu\u00adary 2004, Kather\u00adine be\u00adcame the first com\u00admer\u00adcial pa\u00adtient to re\u00adceive the On\u00adco\u00adtype DX Breast Re\u00adcur\u00adrence Score\u00ae test. She had a Re\u00adcur\u00adrence Score\u00ae re\u00adsult of 18 \u2014 a low score in\u00addi\u00adcat\u00ading she like\u00adly would not ben\u00ade\u00adfit from chemother\u00ada\u00adpy. That num\u00adber wasn\u2019t just da\u00adta \u2014 it was a turn\u00ading point for Kather\u00adine and for the more than 2 mil\u00adlion pa\u00adtients that have used the On\u00adco\u00adtype DX test since then.<\/p>\n
The im\u00adme\u00addi\u00adate ben\u00ade\u00adfit was per\u00adson\u00adal and pro\u00adfound: Kather\u00adine avoid\u00aded months of tox\u00adic treat\u00adment and the long tail of pos\u00adsi\u00adble side ef\u00adfects. Twen\u00adty-two years lat\u00ader, Kather\u00adine re\u00admains can\u00adcer-free*. To\u00adday, she and her hus\u00adband, Mel \u2014 both re\u00adtired \u2014 spend their time ski\u00ading, bik\u00ading, and hik\u00ading in the Sier\u00adras with their dog, Crit\u00adter.<\/p>\n
\n<\/p>\n
\u201cI feel so blessed\u00a0I had the op\u00adpor\u00adtu\u00adni\u00adty to be the first to take this test, forego chemother\u00ada\u00adpy, and learn my po\u00adten\u00adtial for dis\u00adtant re\u00adcur\u00adrence. Very im\u00adpor\u00adtant\u00adly, I want\u00aded to help oth\u00ader women learn about this test so they could have a say in their own, tai\u00adlored can\u00adcer treat\u00adment,\u201d Kather\u00adine, who is now an On\u00adco\u00adtype DX Pa\u00adtient Am\u00adbas\u00adsador, re\u00adcent\u00adly shared.\n<\/p>\n
Kather\u00adine\u2019s sto\u00adry il\u00adlus\u00adtrates the hu\u00adman side of pre\u00adci\u00adsion on\u00adcol\u00ado\u00adgy: per\u00adson\u00adal\u00adized treat\u00adment plans, few\u00ader side ef\u00adfects, pre\u00adserved qual\u00adi\u00adty of life, and \u2014 most im\u00adpor\u00adtant\u00adly \u2014 peace of mind. When you mul\u00adti\u00adply the ef\u00adfect of a bet\u00adter de\u00adci\u00adsion across mil\u00adlions of pa\u00adtients, the sto\u00adry be\u00adcomes more than clin\u00adi\u00adcal \u2014 it high\u00adlights the eco\u00adnom\u00adic val\u00adue of the test.\n<\/p>\n
The Health Eco\u00adnom\u00adics Be\u00adhind Bet\u00adter Care<\/p>\n
Af\u00adter more than two decades of clin\u00adi\u00adcal ev\u00adi\u00addence and re\u00adal-world use in more than 100 coun\u00adtries, more than two mil\u00adlion breast can\u00adcer pa\u00adtients1 and their care teams have used the On\u00adco\u00adtype DX test to help guide their de\u00adci\u00adsion-mak\u00ading. The On\u00adco\u00adtype DX Breast Re\u00adcur\u00adrence Score test de\u00adliv\u00aders per\u00adson\u00adal\u00adized ge\u00adnom\u00adic re\u00adsults to help guide treat\u00adment de\u00adci\u00adsions for pa\u00adtients with ear\u00adly-stage HR+, HER2- breast can\u00adcer. Twen\u00adty-two years af\u00adter launch, the On\u00adco\u00adtype DX Breast Re\u00adcur\u00adrence Score test is the on\u00adly ge\u00adnom\u00adic test proven to pre\u00addict chemother\u00ada\u00adpy ben\u00ade\u00adfit from ran\u00addom\u00adized con\u00adtrolled stud\u00adies2, guid\u00ading per\u00adson\u00adal\u00adized treat\u00adment de\u00adci\u00adsions with the high\u00adest lev\u00adel of ev\u00adi\u00addence.\n<\/p>\n
Prog\u00adnos\u00adtic and pre\u00addic\u00adtive tests serve very dif\u00adfer\u00adent pur\u00adpos\u00ades; prog\u00adnos\u00adtic tests pro\u00advide in\u00adsight in\u00adto how can\u00adcer may be\u00adhave over time \u2014 such as the like\u00adli\u00adhood of re\u00adcur\u00adrence \u2014 but they do not pro\u00advide in\u00adfor\u00adma\u00adtion about treat\u00adment ben\u00ade\u00adfits. Pre\u00addic\u00adtive bio\u00admark\u00aders, on the oth\u00ader hand, help de\u00adter\u00admine whether a pa\u00adtient is like\u00adly to ben\u00ade\u00adfit from a spe\u00adcif\u00adic ther\u00ada\u00adpy, in\u00adfor\u00adma\u00adtion that can di\u00adrect\u00adly guide treat\u00adment choice and sup\u00adport more in\u00addi\u00advid\u00adu\u00adal\u00adized care.3\n<\/p>\n
When a test can pre\u00addict chemother\u00ada\u00adpy ben\u00ade\u00adfit and safe\u00adly re\u00adduce its use, there are both clin\u00adi\u00adcal and fi\u00adnan\u00adcial ben\u00ade\u00adfits. By iden\u00adti\u00adfy\u00ading who is \u2014 and is not \u2014 like\u00adly to ben\u00ade\u00adfit, the test has en\u00adabled clin\u00adi\u00adcians and pa\u00adtients to de-es\u00adca\u00adlate treat\u00adment con\u00adfi\u00addent\u00adly. \u00a0An es\u00adti\u00admat\u00aded 1.6 mil\u00adlion4 of the 2 mil\u00adlion pa\u00adtients test\u00aded world\u00adwide may have been spared from po\u00adten\u00adtial\u00adly un\u00adnec\u00ades\u00adsary chemother\u00ada\u00adpy, avoid\u00ading the acute and long-term tox\u00adi\u00adc\u00adi\u00adties of treat\u00adment.\n<\/p>\n
Chemother\u00ada\u00adpy is ex\u00adpen\u00adsive, but its true cost ex\u00adtends be\u00adyond treat\u00adment ac\u00adqui\u00adsi\u00adtion. There are in\u00adfu\u00adsion vis\u00adits, sup\u00adport\u00adive med\u00adica\u00adtions, man\u00adage\u00adment of side ef\u00adfects, as well as emer\u00adgency vis\u00adits and ad\u00admis\u00adsions for com\u00adpli\u00adca\u00adtions. There are al\u00adso in\u00addi\u00adrect bur\u00addens: di\u00admin\u00adished qual\u00adi\u00adty of life, time away from work, care\u00adgiv\u00ader strain, trav\u00adel costs, and pro\u00adduc\u00adtiv\u00adi\u00adty loss\u00ades.\n<\/p>\n